RAPT Therapeutics Inc. (RAPT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.18 |
Market Cap | 40.90M |
Revenue (ttm) | 4.75M |
Net Income (ttm) | -96.59M |
EPS (ttm) | -2.78 |
PE Ratio (ttm) | -0.42 |
Forward PE | -0.92 |
Analyst | Hold |
Ask | 1.26 |
Volume | 1,413,653 |
Avg. Volume (20D) | 3,537,970 |
Open | 1.22 |
Previous Close | 1.22 |
Day's Range | 1.15 - 1.24 |
52-Week Range | 0.79 - 27.35 |
Beta | 0.32 |
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...
Analyst Forecast
According to 10 analyst ratings, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 241.88% from the latest price.